Risks and Benefits of Phase 1 Oncology Trials, 1991 through 2002
Risks and Benefits of Phase 1 Oncology Trials, 1991 through 2002
Previous reviews of phase 1 oncology trials reported a rate of response to treatment of 4 to 6 percent and a toxicity-related death rate of 0.5 percent. These results may not reflect the rates in current phase 1 oncology trials.We reviewed all nonpediatric phase 1 oncology trials sponsored by the …